EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers

Ayat Lashen, Mashael Algethami, Shatha Alqahtani, Ahmed Shoqafi, Amera Sheha, Jennie N Jeyapalan, Nigel P Mongan, Emad A Rakha iD, Srinivasan Madhusudan iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25074060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ayat Lashen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Naaz Coker Ovarian Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingh…. Hauptthemen laut MEDLINE: Retinoblastoma, Ovarian Neoplasms, Retinal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Naaz-Coker Ovarian Cancer Research Centre, Naaz Coker Ovarian Cancer Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylated retinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging targets in ovarian cancer therapeutics. In the current study, we evaluated the prognostic and predictive significance of the CDK2/4/6–cyclin D1/E1–pRB1 axis in clinical ovarian cancers (OC). The CDK2/4/6, cyclin D1/E1 and RB1/pRB1 protein expression were investigated in 300 ovarian cancers and correlated with clinicopathological parameters and patient outcomes. CDK2/4/6, cyclin D1/E1 and RB1 mRNA expression were evaluated in the publicly available ovarian TCGA dataset. We observed nuclear and cytoplasmic staining for CDK2/4/6, cyclins D1/E1 and RB1/pRB1 in OCs with varying percentages. Increased nuclear CDK2 and nuclear cyclin E1 expression was linked with poor progression-free survival (PFS) and a shorter overall survival (OS). Nuclear CDK6 was associated with poor OS. The cytoplasmic expression of CDK4, cyclin D1 and cyclin E1 also has predictive and/or prognostic significance in OCs. In the multivariate analysis, nuclear cyclin E1 was an independent predictor of poor PFS. Tumours with high nuclear cyclin E1/high nuclear CDK2 have a worse PFS and OS. Detailed bioinformatics in the TCGA cohort showed a positive correlation between cyclin E1 and CDK2. We also showed that cyclin-E1-overexpressing tumours are enriched for genes involved in insulin signalling and release. Our data not only identified the prognostic/predictive significance of these key cell cycle regulators but also demonstrate the importance of sub-cellular localisation. CDK2 targeting in cyclin-E1-amplified OCs could be a rational approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaOvarian NeoplasmsRetinal NeoplasmsFemaleHumansCarcinoma, Ovarian EpithelialCyclin D1Cyclin-Dependent Kinase 2Ubiquitin-Protein LigasesRetinoblastoma Binding Proteins

Stichwörter der Autor:innen

CDK2CDK4CDK6Rbcyclin Dcyclin Eovarian cancerprognostic biomarkerstargeted therapy

Substanzen

Cyclin D1CDK2 protein, humanCyclin-Dependent Kinase 2RB1 protein, humanUbiquitin-Protein LigasesRetinoblastoma Binding Proteins

Autor:innen und Institutionen

  • Naaz Coker Ovarian Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK.
  • Department of Pathology, Nottingham University Hospital, City Campus, Nottingham NG5 1PB, UK.
  • Faculty of Medicine and Health Sciences, Centre for Cancer Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington LE12 5RD, UK.
  • Department of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA.
  • Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.

ORCID-Profile: Emad A Rakha, Srinivasan Madhusudan

Förderung

  • Naaz-Coker Ovarian Cancer Research Centre
  • Naaz Coker Ovarian Cancer Research Centre

Zitieren

APA

Lashen, A., Algethami, M., Alqahtani, S., Shoqafi, A., Sheha, A., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2024). The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25074060

Vancouver

Lashen A, Algethami M, Alqahtani S, Shoqafi A, Sheha A, Jeyapalan JN, et al. The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25074060

BibTeX
@article{Lashen2024,
  author = {Lashen, Ayat and Algethami, Mashael and Alqahtani, Shatha and Shoqafi, Ahmed and Sheha, Amera and Jeyapalan, Jennie N and Mongan, Nigel P and Rakha, Emad A and Madhusudan, Srinivasan},
  title = {The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25074060}
}
Kostenlos starten →